1AD AdAlta Limited
—Mkt Cap: —P/E: —1d ago
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in …
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value6.88M USD
Revenue (TTM)279.37K USD
Gross Profit89.55K USD
Net Income (TTM)-3.24M USD
Revenue/Share0.00 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees2
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU0000001AD2
Valuation
P/E (Trailing)—
P/E (Forward)-0.12
PEG—
EV/EBITDA-2.31
EV/Revenue24.63
P/S27.81
P/B—
EPS (TTM)0.00
EPS (Forward)-0.03
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin32.05%
Oper. Margin-2250.98%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1265.31%
ROA-272.07%
Growth
Revenue Growth-67.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.07M USD
CapEx (TTM)—
FCF Margin-503.39%
FCF Yield—
Net Debt-887.56K USD
Net Debt/EBITDA0.30
Balance Sheet
Debt/Equity—
Current Ratio1.27
Quick Ratio1.15
Book Value/Sh0.00 AUD
Cash/Share0.00 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.3.21B
Float1.38B
Insiders56.81%
Institutions2.33%
Technical
SMA 500.0033 AUD
SMA 2000.0040 AUD
Beta0.14
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)498.69K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—